Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To investigate the impact of canagliflozin on secretion of gut hormones, in particular glucagon-like peptide 1 (GLP-1) in gastric bypass operated patients.
Glucose is a potent stimulus for GLP-1 secretion after gastric bypass surgery and the SGLT-1 transporter appears to be crucial for this response. The study will investigate the effects of SGLT-1/SGLT-2 inhibition (by canagliflozin) on secretion of GLP-1 and other gut hormones after gastric bypass surgery.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Glucose | Experimental |
| |
| Glucose + Canagliflozin | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Glucose | Dietary Supplement | Ingestion of glucose (50 g) dissolved in 200 ml water. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Difference in GLP-1 secretion (evaluated by iAUC). | Comparison of the GLP-1 responses (evaluated by iAUC) between the two test days. | 0-240 min following glucose ingestion |
| Measure | Description | Time Frame |
|---|---|---|
| Difference in glucose responses between the two test days. | 0-240 min following glucose ingestion | |
| Difference in insulin responses between the two test days. | 0-240 min following glucose ingestion |
Not provided
Inclusion Criteria:
•Uncomplicated gastric bypass surgery performed minimum 12 months prior to study
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sten Madsbad, Professor | Contact | +4538623032 | sten.madsbad@regionh.dk |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dept. of Endocrinology | Recruiting | Hvidovre | 2650 | Denmark |
Not provided
| ID | Term |
|---|---|
| D050177 | Overweight |
| D009765 | Obesity |
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
Not provided
Not provided
| ID | Term |
|---|---|
| D005947 | Glucose |
| D000068896 | Canagliflozin |
| ID | Term |
|---|---|
| D006601 | Hexoses |
| D009005 | Monosaccharides |
| D000073893 | Sugars |
| D002241 | Carbohydrates |
| D013876 |
Not provided
Not provided
10 gastric bypass patients
Not provided
Not provided
Not provided
| Glucose + Canagliflozin |
| Dietary Supplement |
Ingestion of glucose (50 g) dissolved in 200 ml water combined with the SGLT-1/SGLT-2 inhibitor canagliflozin. |
|
| Difference in C-peptide responses between the two test days. | 0-240 min following glucose ingestion |
| Difference in Gastric Inhibitory Peptide (GIP) responses (evaluated by iAUC) between the two test days. | 0-240 min following glucose ingestion |
| Difference in peptide YY (PYY) responses (evaluated by iAUC) between the two test days. | 0-240 min following carbohydrate ingestion |
| Difference in glucagon responses (evaluated by iAUC) between the two test days. | 0-240 min following glucose ingestion |
| Difference in oxyntomodulin responses (evaluated by iAUC) between the two test days. | 0-240 min following carbohydrate ingestion |
| Difference in cholecystokinin (CCK) responses (evaluated by iAUC) between the two test days. | 0-240 min following glucose ingestion |
| Difference in bile acid responses (evaluated by iAUC) between the two test days. | 0-240 min following glucose ingestion |
| D012816 |
| Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| Thiophenes |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D005960 | Glucosides |
| D006027 | Glycosides |